Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain.
Carlos Escobar CervantesJulio Martí-AlmorAlejandro Isidoro Pérez CabezaKevin BowrinAleix Llorac MoixMar Genís GironèsDavid GascheAurélie MillierJean TarduMondher ToumiJean-Baptiste BrièrePublished in: PloS one (2022)
These results suggest that rivaroxaban and dabigatran are cost-effective versus vitamin K antagonist for stroke prevention in non-valvular atrial fibrillation, from the Spanish National Health System perspective.